Rocket Pharmaceuticals is trading 5.9% down at $3.21 as the stock pulls back from yesterday's significant gains.
- The stock jumped over 10% on August 3, 2026, following a positive Phase 2 safety update for its Danon disease gene therapy candidate, RP-A501.
- Today's downward move is viewed as a normal consolidation as traders digest the recent rally, with no fresh negative news reported.